Results 1 to 10 of about 12,264 (94)

TRIM29 reverses lenvatinib resistance in liver cancer cells by ubiquitinating and degrading YBX1 to inhibit the PI3K/AKT pathway [PDF]

Translational Oncology
Sorafenib and lenvatinib are frontline treatments for advanced hepatocellular carcinoma (HCC). While lenvatinib surpasses sorafenib in efficacy and tolerability, resistance remains a significant clinical challenge.
Yuhong Tang, Songong Fan, Rui Peng, Huanxiang Liu, Bingbing Su, Daoyuan Tu, Shunyi Wang, Xin Jin, Guoqing Jiang, Shengjie Jin, Chi Zhang, Jun Cao, Dousheng Bai   +12 more
doaj   +4 more sources

Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma

Cells, 2023
Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits ...
Katsuki Miyazaki, Yuji Morine, Caiming Xu, Chiharu Nakasu, Yuma Wada, Hiroki Teraoku, Shinichiro Yamada, Yu Saito, Tetsuya Ikemoto, Mitsuo Shimada, Ajay Goel   +10 more
doaj   +3 more sources

Deubiquitinase USP32 stabilizes DDX17 to promote tumor progression and lenvatinib resistance in hepatocellular carcinoma via the miR-3163/MAPK pathway [PDF]

Cell Death and Disease
Lenvatinib, a first-line therapy for hepatocellular carcinoma (HCC), is frequently compromised by the development of acquired resistance. Although aberrant protein ubiquitination contributes to drug resistance, the underlying mechanisms remain ...
Yang Yu, Bo-Rui Xu, Hao-Ran Huang, Zi-Wen Nong, Fei-Feng Wu, Guo-Pei Zhang, Shao-Qiang Li   +6 more
doaj   +2 more sources

RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis [PDF]

Molecular Biomedicine
Hepatocellular carcinoma (HCC) constitutes a formidable global health challenge. Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI), has gradually become a cornerstone therapeutic agent for advanced HCC; however, the emergence of drug ...
Xiaomeng Yao, Yunkai Lin, Pingping Chen, Mengyou Xu, Mengmiao Pei, Xinru Fan, Huibo Feng, Xinhao Xing, Jiaqi Guo, Yang Liu, Xinzhu Quan, Yufei Pan, Yexiong Tan, Huabang Zhou, Liwei Dong, Hui Wang, Heping Hu   +16 more
doaj   +2 more sources

HKDC1-mediated polyamine rewiring drives lenvatinib resistance and immune escape in hepatocellular carcinoma [PDF]

Clinical and Molecular Hepatology
Background/Aims Lenvatinib resistance and immune exclusion limit outcomes in hepatocellular carcinoma (HCC). We hypothesized that metabolic rewiring orchestrates resistance to lenvatinib and programmed cell death protein 1 (PD-1) blockade.
Shiping Chen, Biao Wang, Yang Zhang, Bing Quan, Yujie Shao, Guiqi Zhu, Jialiang Cai, Peiling Zhang, Lina Song, Jinglei Wan, Yi Yang, Junxian Du, Yufan Cai, Zhi Dai   +13 more
doaj   +2 more sources

SERPINE2-mediated activation of JAK2/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma [PDF]

Journal of Experimental & Clinical Cancer Research
Background Acquired resistance remains a major obstacle in molecular-targeted therapy for advanced hepatocellular carcinoma (HCC). This study aimed to elucidate the role and underlying mechanisms of SERPINE2 in mediating lenvatinib resistance by ...
Kan Liu, Shenglan Huang, Yongkang Xu, Ye Mao, Ning Chen, Yixin Yuan, Qinwen Xiao, Shumin Fu, Jianbing Wu   +8 more
doaj   +2 more sources

DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway [PDF]

Advanced Science
Lenvatinib serves as a first‐line therapy for advanced hepatocellular carcinoma (HCC), but its clinical efficacy is severely limited by acquired drug resistance. Consequently, the identification of therapeutic targets to reverse lenvatinib resistance may
Shiguang Yang, Jie Li, Shengwei Mao, Xuhui Zhao, Douwaner Liu, Jiafeng Chen, Jialu Fu, Yichao Bu, Xiaoling Wu, Shaoqing Liu, Qifeng Yu, Qiongzhu Dong, Zheng Tang, Yuan Fang, Yinghong Shi   +14 more
doaj   +2 more sources

Annexin A3 potentiates lenvatinib resistance in hepatocellular carcinoma through multiple approaches amplified by a positive feedback loop [PDF]

Cell Death and Disease
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies with limited treatment options. Lenvatinib is a first-line drug for advanced HCC. However, its effect on patient survival is limited and patients ultimately develop disease progression
Yingqin Zhu, Yue Huang, Mengjia Song, Jieying Yang, Jingjing Zhao, Yan Tang, Dijun Ouyang, Chaopin Yang, Yuanyuan Chen, Qijing Wang, Yongqiang Li, Jia He, Hao Chen, Tong Xiang, Jianchuan Xia, Qiuzhong Pan   +15 more
doaj   +2 more sources

Identification and validation of a lenvatinib resistance-related prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance [PDF]

BMC Gastroenterology
Background Drug resistance reflects the evolution of tumors and represents the leading factor behind recurrence and death. Lenvatinib is the first-line therapy for hepatocellular carcinoma (HCC), but its effectiveness is limited by rapid development of ...
Jinfeng Wang, Jianfei Shi, Lili Mi, Ning Li, Xin Han, Man Zhao, Xiaoling Duan, Guangjie Han, Jiaojiao Hou, Fei Yin   +9 more
doaj   +2 more sources

COLEC12 tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling [PDF]

Clinical and Molecular Hepatology
Background/Aims Lenvatinib resistance remains a critical barrier in advanced hepatocellular carcinoma (HCC) therapy. However, the underlying mechanisms and strategies for reversing resistance remain incompletely understood.
Jianxing Zhang, Liang Qiao, Zongfeng Wu, Dinglan Zuo, Shanshan Huang, Shaoru Liu, Zhenkun Huang, Yi Zeng, Yu Li, Yichuan Yuan, Chenwei Wang, Wei He, Jiliang Qiu, Yunfei Yuan, Yi Niu, Binkui Li   +15 more
doaj   +2 more sources